Area of research
Oncology · Hematology
Research interest
Research focused on CD8 and Cytotoxic T cell, with related work in Immunology, Natural (archaeology), Degranulation. Notable publications include 'Advantages and applications of CAR-expressing natural killer cells', 'Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of...', and 'Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial'.
Adoptive transfer of regulatory T cells in pediatric patients with treatment-refractory acute graft-versus-host disease
Point-of-Care Anti–CD19-CAR T-cell Therapy Induces Renal Remission in Refractory Myeloperoxidase–Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform
GMP-compatible manufacturing of three iPS cell lines from human peripheral blood
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved <i>Ex Vivo</i> Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial
Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L <sup>+</sup> T Cells for Manufacturing of Gene Therapy Medicinal Products
Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms
Advantages and applications of CAR-expressing natural killer cells
Increased sMICA and TGFβ <sub>1</sub> levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells
Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells